Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 38 results
Filters: First Letter Of Last Name is C  [Clear All Filters]
Found 38 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

C

Cachay ER, Frost SDW, Richman DD, Smith DM, Little SJ. "Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection." J. Infect. Dis.. 2007;195(9):1270-7.
Campbell TB, Smeaton LM, Kumarasamy N, et al. "Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings." PLoS Med.. 2012;9(8):e1001290.
Canter JA, Robbins GK, Selph D, et al. "African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy." J. Infect. Dis.. 2010;201(11):1703-7.
Canter JA, Haas DW, Kallianpur AR, et al. "The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy." Pharmacogenomics J.. 2008;8(1):71-7.
Cao YJun, Flexner CW, Dunaway S, et al. "Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers." Antimicrob. Agents Chemother.. 2008;52(5):1630-4.
Carlson JM, Brumme CJ, Martin E, et al. "Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1." J. Virol.. 2012;86(24):13202-16.
Castillo-Mancilla JR, Aquilante CL, Wempe MF, et al. "Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)." J. Antimicrob. Chemother.. 2016;71(6):1609-18.
Castillo-Mancilla JR, Cohn SE, Krishnan S, et al. "Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials." HIV Clin Trials. 2014;15(1):14-26.
Cespedes MS, Kerns SL, Holzman RS, McLaren PJ, Ostrer H, Aberg JA. "Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268." HIV Clin Trials. 2013;14(6):292-302.
Cespedes MS, Aberg JA. "Neuropsychiatric complications of antiretroviral therapy." Drug Saf. 2006;29(10):865-74.
Chan ES, Landay AL, Brown TT, et al. "Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir." AIDS. 2016;30(13):2091-7.
J Chang J, Woods M, Lindsay RJ, et al. "Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication." J. Infect. Dis.. 2013;208(5):830-8.
Chen H, Clifford DB, Deng L, et al. "Peripheral neuropathy in ART-experienced patients: prevalence and risk factors." J. Neurovirol.. 2013;19(6):557-64.
Chew KW, Hua L, Bhattacharya D, et al. "The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection." Open Forum Infect Dis. 2014;1(3):ofu104.
Chow D, Chen H, Glesby MJ, et al. "Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients." AIDS. 2009;23(16):2133-41.
Chung RT, Umbleja T, Chen JY, Andersen JW, Butt AA, Sherman KE. "Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients." HIV Clin Trials. 2012;13(2):70-82.
Ciaranello AL, Lockman S, Freedberg KA, et al. "First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial." AIDS. 2011;25(4):479-92.
Cillo AR, Hilldorfer BB, Lalama CM, et al. "Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery." AIDS. 2015;29(16):2121-9.
Cillo AR, Krishnan S, McMahon DK, Mitsuyasu RT, Para MF, Mellors JW. "Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy." PLoS ONE. 2014;9(3):e92118.
Cimbro R, Vassena L, Arthos J, et al. "IL-7 induces expression and activation of integrin α4β7 promoting naive T-cell homing to the intestinal mucosa." Blood. 2012;120(13):2610-9.
Clark SA, Shulman NS, Bosch RJ, Mellors JW. "Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors." AIDS. 2006;20(7):981-4.
Clifford DB, Smurzynski M, Park LS, et al. "Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients." Neurology. 2009;73(4):309-14.
Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. "Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)." HIV Clin Trials. 2009;10(6):343-55.
Cohen MS, Chen YQ, McCauley M, et al. "Prevention of HIV-1 infection with early antiretroviral therapy." N. Engl. J. Med.. 2011;365(6):493-505.
Cohn SE, Park J-G, Watts DH, et al. "Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions." Clin. Pharmacol. Ther.. 2007;81(2):222-7.
Cohn SE, Umbleja T, Mrus J, Bardeguez AD, Andersen JW, Chesney MA. "Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084." AIDS Patient Care STDS. 2008;22(1):29-40.
Cohn SE, Jiang H, J McCutchan A, et al. "Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362." AIDS Care. 2011;23(6):775-85.
Colantuoni E, Rosenblum M. "Leveraging prognostic baseline variables to gain precision in randomized trials." Stat Med. 2015;34(18):2602-17.
Collier AC, Tierney C, Downey GF, et al. "Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV." HIV Clin Trials. 2008;9(2):91-102.
Connick E, Bosch RJ, Aga E, Schlichtemeier R, Demeter LM, Volberding P. "Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection." J. Acquir. Immune Defic. Syndr.. 2011;58(1):1-8.

Pages